David Brower joined Accent in September 2018 and serves as our Chief Business Officer, responsible for business development, portfolio strategy, and finance at Accent. David has held a range of life science business development, strategy, and investing roles. Prior to joining Accent, David led the business development function for Blueprint Medicines, where he completed a variety of strategic transactions, including its seminal partnerships with Roche Pharmaceuticals, CStone Pharmaceuticals, and Alexion Pharmaceuticals. Prior to Blueprint Medicines, David was a member of Pfizer Pharmaceuticals’ Worldwide Business Development team, focusing on licensing and M&A transactions and business development strategy. He was previously a healthcare trader and investor for Lehman Brothers and Barclays Capital. David received his MBA with a concentration in healthcare from the Wharton School of Business at the University of Pennsylvania and his BA in biology from Dartmouth College.